Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 3/20 | 0.41 |
| ▸ | FNTB | P49356 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | MME | P08473 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26645910 | 1.00 | KDM4E (0.44) | KDM4EKMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL24722846 | 0.94 | KDM4E (0.48) | KDM4EKMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL24722840 | 0.94 | KDM4E (0.48) | KDM4EKMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL17347452 | 0.92 | PTGS1 (0.44) | KDM4EKMT2AALDH1A1MAPTPTGS1 | |
| SCHEMBL25413152 | 0.89 | PTGS1 (0.52) | KDM4EKMT2AALDH1A1MAPTPTGS1 | |
| SCHEMBL25413149 | 0.89 | PTGS1 (0.52) | KDM4EKMT2AALDH1A1MAPTPTGS1 | |
| SCHEMBL20960454 | 0.89 | PTGS1 (0.36) | KDM4EKMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL17722908 | 0.89 | PTGS1 (0.36) | KDM4EKMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL23071860 | 0.88 | FNTA (0.47) | KDM4EKMT2AFNTAFNTBALDH1A1 | |
| SCHEMBL27339052 | 0.88 | KDM4E (0.39) | KDM4EKMT2AFNTAFNTBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543924-A2 | HUMAN CD33 ANTIBODIES AND GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4522222-A1 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | Eli Lilly and Company (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4518906-A1 | HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | Eli Lilly and Company (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240173425-A1 | HUMAN CD33 ANTIBODIES AND GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240100176-A1 | HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY | 2024-03-28 | — | — | US | disclosed |
| US-20240082414-A1 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY | 2024-03-14 | — | — | US | disclosed |
| WO-2023250341-A2 | HUMAN CD33 ANTIBODIES AND GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023250341-A2 | HUMAN CD33 ANTIBODIES AND GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023235738-A1 | HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023220549-A1 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220549-A1 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173425-A1 | HUMAN CD33 ANTIBODIES AND GLUCOCORTICOID CONJUGATES | FCGR3B, FCGR1A, FCGR2A | KDM4E 3739/4885KMT2A 1901/4885FNTA 2196/4885 |
| US-20240100176-A1 | HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | IL4, IL2RA, IL2 | KDM4E 3180/4885KMT2A 2563/4885FNTA 1141/4885 |
| US-20240082414-A1 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | TNFRSF1A, CD40, TNFRSF9 | KDM4E 4597/4885KMT2A 4025/4885FNTA 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.